Latest Helus Pharma News & Updates

See the latest news and media coverage for Helus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Helus Pharma (Helus)

Mental health biopharmaceutical company developing serotonergic agonists

helus.com

Headquarters: Toronto, Canada
Founded year: 2019
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated October 6

Latest news about Helus Pharma (Helus)

In short: Helus, formerly Cybin, appointed Michael Halstead CEO, completed HLP003 Phase 3 enrollment, and reported Q1 FY2027 results.

Company announcements

October 1 Helus

Helus Pharma completes legal name change from Cybin Inc

The company rebranded effective October 1, 2026, to reflect its transformation into a commercial-ready pharmaceutical entity while maintaining the HELP ticker symbol.

August 27 Helus

Helus shares HLP003 Phase 2 results and CEO insights

Michael Halstead highlights clinical trial data during a keynote at the Canaccord Genuity conference to outline his strategic commitment to mental health treatment innovation.

August 3 Helus

Helus Pharma appoints Michael Halstead as Chief Executive Officer

Halstead, former President of Intra-Cellular Therapies, led its US$14.6 billion sale to Johnson & Johnson and will guide HLP003 through Phase 3 readout expected Q4 2026.

July 21 Helus

Helus completes enrollment in Phase 3 APPROACH study of HLP003

The study evaluates HLP003 as an adjunctive treatment for major depressive disorder, ahead of schedule.

Media coverage

October 6 Kalkine

Helus Pharma Stock Drops 7.29% as Volatility Builds Ahead of Pivotal Phase 3 APPROACH Readout for HLP003 (CN:HELP)

The company was formerly known ... to Helus Pharma Inc. on 1 October 2026. Download Free Report – Explore 3 Stock Ideas & Industry Insights...

September 21 Investing.com

Helus Pharma presents data on the drug candidate HLP003 for depression

NEW YORK and TORONTO - Helus Pharma (NASDAQ:HELP) (Cboe CA:HELP) presented four evaluation posters on HLP003, an experimental oral deuterated analogue of psilocin...

September 20 Yahoo Finance

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline...

September 18 Yahoo Finance

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thu...

Never miss news about Helus

Track Helus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Helus competitors & trending companies

Browse news for competitors to Helus and other trending companies.